Papillary Thyroid Carcinoma

Mazzaferri, Ernest L.; Young, Robert L.; Oertel, James E.; Kemmerer, William T.; Page, Carey P.

doi:10.1097/00005792-197705000-00001

Cited by 479 publications

(50 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was only one patient (0.3%) who showed local recurrence and after the second surgery, she has maintained a disease-free status. Previous studies have reported that the suppression of serum TSH levels could reduce cancer-specific mortality or disease recurrence, especially in high-risk patients [11,12,13,14,15]. They agreed that extreme low TSH suppression could give better prognosis to patients with high-risk DTC.…”

Section: Discussionmentioning

confidence: 92%

Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy

Lee

Jeon

Kim

et al. 2019

JCM

View full text Add to dashboard Cite

Background: This study aimed to identify the clinical results after thyrotropin suppression therapy (TST) cessation and evaluated clinical factors associated with successful TST cessation. Methods: Patients who underwent lobectomy due to low-risk papillary thyroid carcinoma (PTC) were included in this study. We compared clinical characteristics and outcomes between patients who succeeded to stop TST and failed to stop TST. Results: A total of 363 patients were included in the study. One hundred and ninety-three patients (53.2%, 193/363) succeeded to stop TST. The independent associated factors for successful TST cessation were the preoperative thyroid-stimulating hormone (TSH) level and the maintenance period of TST. Patients with low TSH level showed a higher success rate for levothyroxine (LT4) cessation than patients with high TSH level (1.79 ± 1.08 and 2.76 ± 1.82 mU/L, p < 0.001). Patients who failed to discontinue TST showed a longer maintenance period of TST than patients who succeeded to discontinue TST (54.09 ± 17.44 and 37.58 ± 17.68 months, p < 0.001). Conclusions: Preoperative TSH level and maintenance period of TST are important factors for successful cessation of TST. If TST cessation is planned for patients who are taking LT4 after lobectomy, a higher success rate of TST cessation is expected with low preoperative TSH level and early cessation of LT4.

show abstract

Section: Discussionmentioning

confidence: 92%

Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy

Lee

Jeon

Kim

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Even when the tumors did not regress in response to I3'I, yet were controlled by suppression, the control was attributed to the '311. 1 We have also compared the cost of treatment of papillary carcinoma by the method used at the Cleveland Clinic with the cost of that used at the University of Michigan Medical School Center. Varma et ~1 1 .~ have given full details of the treatments that have been given routinely to and are recommended for all patients with papillary cancer of the thyroid.…”

Section: A Comparison Of the Results Of Treatment By Suppression And mentioning

confidence: 99%

The advantages of subtotal thyroidectomy and suppression of TSH in the primary treatment of papillary carcinoma of the thyroid

Crile

Antunez

Esselstyn

et al. 1985

Cancer

View full text Add to dashboard Cite

Patients between the ages of 6 and 45 years with distant metastases from papillary carcinoma of the thyroid can be treated as effectively by subtotal thyroidectomy and suppressive doses of thyroid hormone as by total thyroidectomy followed by treatment with iodine 131 (131I). Moreover, distant metastases can be treated by either 131I or suppression as effectively after they are apparent on x‐ray as they can be when treated in a subclinical stage. Therefore, in patients younger than 45 years old it is rarely necessary to perform a total thyroidectomy or to do frequent postoperative scans. In patients older than 44 or younger than 7 who have distant metastases or extensive involvement of both lobes, total or almost total thyroidectomy is justified if it can be done with minimal morbidity. In patients of this age group whose tumors fail to respond to suppressive doses of thyroid, 131I should be used. In view of the importance of diagnostic related groups (DRG) to the economy of hospitals, we note that the cost of total thyroidectomy, ablation by 131I, and intermittent body scans is at least three times that of less radical procedures which, in conjunction with suppression by thyroid feeding, give the same survival with less morbidity.

show abstract

“…Specifically concerning the thyroid, ERs have been described in both neoplastic and nonneoplastic thyroid tissue, though the results are not consistent to date, likely because of differences in the sensitivity of the techniques employed [15,16]. The role of estrogens in the development and evolution of DTC has been widely analyzed in several studies [20,21,22,23,24,25,26,27,28]. A recent meta-analysis including >5,000 patients reported that menopausal women had a reduced thyroid cancer risk, whereas increasing age at first pregnancy/birth was associated with a higher cancer risk [29].…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer

Sturniolo¹,

Zafón²,

Moleti³

et al. 2016

Eur Thyroid J

View full text Add to dashboard Cite

Background: Papillary thyroid cancer (PTC) prevalence is nearly 3 times higher in females than in males. This gender difference suggests that growth and progression of PTC might be influenced by female sex hormones. Objectives: To analyze the expression of both estrogen receptor (ER)-α and progesterone receptor (PR) by immunohistochemistry in 203 PTC patients. Methods: ER-α and PR expression was evaluated in paraffin-embedded tumor tissue samples of 45 males and 158 females followed up for 7.2 ± 3.7 years. Results: ER-α was expressed in 52 (25.6%) patients (41 females and 11 males) and PR in 94 (46.3%) patients (75 females and 19 males). ER-α and PR were coexpressed in 31 (15.3%) patients (27 females and 4 males). ER-α expression correlated significantly with tumor size in the whole sample (ER-α positive 22.8 ± 11.8 mm vs. ER-α negative 15.1 ± 12.4 mm; p = 0.02) and in the subgroup of women (ER-α positive 18.8 ± 12.8 mm vs. ER-α negative 14.9 ± 12.3 mm; p = 0.048). In addition, ER-α expression significantly correlated with remission of the disease. In fact, of the 192 patients followed up, 50/153 (32.7%) disease-free patients were ER-α positive, in contrast to only 3/39 (7.7%) with evidence of disease persistence/recurrence (χ² = 8.5, p = 0.0036). PR expression was not associated with any of the parameters analyzed. Conclusions: The present study confirmed recent data indicating that ER-α and PR expression is a common finding in thyroid tumor tissue. However, in contrast to previous reports, we observed an association between ER-α expression and a more favorable outcome in PTC patients.

show abstract

Papillary Thyroid Carcinoma

Cited by 479 publications

References 0 publications

Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy

Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy

The advantages of subtotal thyroidectomy and suppression of TSH in the primary treatment of papillary carcinoma of the thyroid

Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer

Contact Info

Product

Resources

About